

17 July 2019

RE: Femme-Tab ED 30/150 and Femme-Tab ED 20/100

Dear Healthcare Professional,

In light of recent shortage of Combined Oral Contraceptive products, Microgynon® (Bayer) and Levlen® (Bayer) in New Zealand, AFT Pharmaceuticals Ltd. would like to inform you that **Femme-Tab ED 20/100** (Ethinylloestradiol 20 mcg + Levonorgestrel 100 mcg) and **Femme-Tab ED 30/150** (Ethinylloestradiol 30 mcg + Levonorgestrel 150 mcg) will be available from 17 July 2019.

Since the stock we are bringing in are currently used for the Australian market, you may observe a few differences.

1. Both Femme-Tab ED 20/100 and Femme-Tab ED 30/150 contain **FOUR** blisters of 28 tablets (21 actives and 7 inactives) in each carton.
2. For **Femme-Tab ED 30/150 only**, the highlighted section on the blister pack layout is different to Levlen®.

Patients are usually instructed to start taking the medicine from the corresponding day within the highlighted section on the blister pack. However, unlike Levlen® in New Zealand, the highlighted section of Femme-Tab ED 30/150 covers 2 active tablets and 5 inactive tablets – the difference is due to the requirements in Australia.


We recommend that the patients in New Zealand be counselled to start the calendar pack in the first seven active tablets;

- If starting on Saturday or Sunday, START with the tablet from the highlighted red section, marked with that day of the week.
 - If starting on Monday to Friday, START with the tablet from the non-highlighted section immediately following the highlighted red section, marked with that day of the week.
3. The package insert (Consumer Medicine Information) has been designed for the Australian territories. In order to minimise any confusion, we have uploaded the New Zealand specific data sheet on the Medsafe website.

To support the smooth transition of the aforementioned products during this out of stock situation, AFT Pharmaceuticals Ltd. would like to encourage any relevant questions to be forwarded to the following contacts

Customer Service Administrator	customer.service@aftpharm.com
Medical Affairs Manager	peter.yoo@aftpharm.com

Yours sincerely,



Peter Yoo

A|F|T Pharmaceuticals Ltd.

- Levlen® and Microgynon® are registered trademarks of the Bayer Group, Germany
- Femme-Tab ED 20/100 and Femme-Tab ED 30/150 are registered Prescription Medicine in New Zealand.
- Please review the data sheet (available at www.medsafe.govt.nz) for information on dosage, contraindications, precautions, interactions and adverse effects.